Pharma & Life Sciences

CCR8 Antibodies and Fusion Proteins for Cancer Treatment

The USPTO published patent application US20260098098A1 covering CCR8-binding antibodies and fusion proteins for cancer treatment. Inventors McGrath et al. filed Application No. 19182473 on April 17, 2025, with the application published on April 9, 2026. The patent covers therapeutic compositions and methods using CCR8-targeted biologics.

Medline ENFit G-Tube Connector Recall - Type II

Health Canada issued a Type II recall for Medline ENFit G-Tube Connectors (ENFIT1010GC) across all lots due to dimensional manufacturing defects. The non-compliant connectors may fail to form proper seals with ENFit devices, causing leakage and potentially delaying patient care during medication administration. Healthcare providers must identify and destroy affected products.

Health Canada Warns Against Unauthorized Injectable Peptides

Health Canada issued a public advisory warning consumers about serious health risks of unauthorized injectable peptide drugs sold online. The advisory identifies 14 specific peptides including BPC-157, Melanotan, TB-500, CJC-1295, and Retatrutide that have been seized as illegal health products. These products marketed for anti-aging, bodybuilding, weight loss, or wellness lack Health Canada safety, efficacy, and quality assessment.

Medline Neuro Sponges Recall - Elevated Endotoxin Risk

Health Canada issued a Type II recall for Medline Neuro Sponges (Gauze Sponges, X-Ray Detectable) due to potential out-of-specification endotoxin levels. Affected products include all lots of eight model numbers (NEUROSPNG05, 02, 13, 06, 07, 14, 09, 11). Elevated endotoxin levels may require medical or surgical intervention, though the likelihood of adverse health consequences is considered remote. Healthcare facilities must destroy recalled products immediately.

Filociclovir (EP3934759A1) for Adenovirus Infection Treatment

The European Patent Office published patent application EP3934759A1 for Filociclovir as a treatment for adenovirus infection, filed by Microbiotix, Inc. and The UAB Research Foundation. Inventors include Terry L. Bowlin and Mark N. Prichard. The patent provides exclusivity for the pharmaceutical compound and its therapeutic use in designated contracting states.

Innate Pharma CD73 Blocking Antibodies Patent EP3959239A1

The European Patent Office granted patent EP3959239A1 to Innate Pharma for CD73 blocking antibodies, covering compositions and methods for treating cancer and infectious diseases. The patent names Laurent Gauthier, Carine Paturel, and Ivan Perrot as inventors and designates all EU member states. Patent protection extends for the standard term under EPC provisions.

Regeneron Autoimmune Disease Antibody Compositions Patent EP3980066A1

The EPO published patent application EP3980066A1 by Regeneron Pharmaceuticals covering methods and compositions for treating autoimmune diseases using antibody-based therapeutics. The application claims compositions targeting immune pathways including A61P 37/02 and A61P 37/06 classifications. The patent designates all EU member states plus several additional European countries.

Omeros Corporation MASP-2 Inhibitors Patent EP4069238A1

The European Patent Office published patent application EP4069238A1 for Omeros Corporation covering MASP-2 (Mannan-Binding Lectin-Associated Serine Protease-2) inhibitor compounds and their therapeutic uses. The patent application covers chemical compositions and methods for treating conditions including metabolic disorders, cardiovascular diseases, respiratory conditions, and inflammatory disorders through MASP-2 inhibition.

Horizon Therapeutics Ireland DAC - Methods for Treatment of Thyroid Eye Disease (EP4021500A1)

EPO published patent application EP4021500A1 filed by Horizon Therapeutics Ireland DAC covering methods for treating thyroid eye disease. The application names Jeffrey Sherman as inventor and includes IPC classifications spanning immunology (A61K 39/395), monoclonal antibodies (C07K 16/28), and ophthalmic therapeutics (A61P 27/02).

Small Molecule Helios Degraders for Cancer Treatment

The European Patent Office published patent application EP4051386A1 for Dana-Farber Cancer Institute's small molecule Helios degrader compounds and methods for treating cancer. The patent application covers A61P 35/00 classifications and 12 different heterocyclic compound formulations under the C07D chemical series. The patent designates all 39 European Patent Convention member states.